Evidence map›Paper›PMID 35931825›Full record

ReviewNature reviews. Neurology2022

The role of the gut microbiota in multiple sclerosis.

Jorge Correale, Reinhard Hohlfeld, Sergio E Baranzini

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 3 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 3 syntheses or guidelines pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. The Gut Microbiome in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2026
    Review
  9. Fecal Microbiota Transplantation BeyondJournal of Korean medical science · 2026
    Review
  10. The Mind From Within: Visceral Roots of Human Cognition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  11. Significant changes in the fecal bacteriobiota richness and diversity in patients with relapsing-remitting multiple sclerosis compared to healthy individuals.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. The neuroimmune system and cognition.Nature immunology · 2026
    Review
  16. Observational
  17. Review
  18. Article
  19. Article
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Jorge CorrealeDepartment of Neurology, Fleni, Buenos Aires, Argentina.ORCID http://orcid.org/0000-0003-4756-9889
Reinhard HohlfeldInstitute of Clinical Neuroimmunology, University Hospital, Ludwig Maximilian University, Munich, Germany.ORCID http://orcid.org/0000-0002-6302-1488
Sergio E BaranziniWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA. sergio.baranzini@ucsf.edu.ORCID http://orcid.org/0000-0003-0067-194X
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia · ARMunich Cluster for Systems Neurology · DEUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the past decade, research has revealed that the vast community of micro-organisms that inhabit the gut - known as the gut microbiota - is intricately linked to human health and disease, partly as a result of its influence on systemic immune responses. Accumulating evidence demonstrates that these effects on immune function are important in neuroinflammatory diseases, such as multiple sclerosis (MS), and that modulation of the microbiome could be therapeutically beneficial in these conditions. In this Review, we examine the influence that the gut microbiota have on immune function via modulation of serotonin production in the gut and through complex interactions with components of the immune system, such as T cells and B cells. We then present evidence from studies in mice and humans that these effects of the gut microbiota on the immune system are important in the development and course of MS. We also consider how strategies for manipulating the composition of the gut microbiota could be used to influence disease-related immune dysfunction and form the basis of a new class of therapeutics. The strategies discussed include the use of probiotics, supplementation with bacterial metabolites, transplantation of faecal matter or defined microbial communities, and dietary intervention. Carefully designed studies with large human cohorts will be required to gain a full understanding of the microbiome changes involved in MS and to develop therapeutic strategies that target these changes.

Indexed as

Gastrointestinal MicrobiomeMicrobiotaMultiple SclerosisProbioticsAnimalsHumansImmune SystemMice

Identifiers

PMID35931825
OpenAlexW4289939079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.